Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow (2021 - 2025)

Kiniksa Pharmaceuticals International's Net Cash Flow history spans 5 years, with the latest figure at -$9.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 110.74% year-over-year to -$9.3 million; the TTM value through Dec 2025 reached -$18.0 million, down 123.78%, while the annual FY2025 figure was -$18.0 million, 123.78% down from the prior year.
  • Net Cash Flow reached -$9.3 million in Q4 2025 per KNSA's latest filing, up from -$17.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $86.2 million in Q4 2024 to a low of -$67.7 million in Q4 2021.
  • Average Net Cash Flow over 5 years is $2.6 million, with a median of $1.7 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: plummeted 1116.6% in 2022, then surged 973.05% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$67.7 million in 2021, then grew by 21.66% to -$53.0 million in 2022, then surged by 81.39% to -$9.9 million in 2023, then soared by 973.05% to $86.2 million in 2024, then tumbled by 110.74% to -$9.3 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Net Cash Flow are -$9.3 million (Q4 2025), -$17.2 million (Q3 2025), and $34.9 million (Q2 2025).